Supplementary Material

Association of Serum Liver Enzymes with Brain Amyloidopathy and Cognitive Performance

Supplementary Table 1. Results of the sensitivity analysis for amyloid PET positivity in liver enzymes within the PSM cohort

	Amyloid PET positivity		
	OR	**95% CI**	**p [a]**
AST, U/L	1.009	0.981–1.038	0.533
ALT, U/L	0.968	0.946–0.990	0.025
AST-to-ALT ratio	1.578	1.144–2.248	0.025
ALP, U/L	0.993	0.984–1.002	0.202
Total bilirubin, mg/dL	1.456	0.662–3.255	0.424
Albumin, g/dL	0.599	0.342–1.037	0.138

All analyses were adjusted for prevalence of hypertension, diabetes mellitus, dyslipidemia, and statin use
[a] Adjusted p value for FDR
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; FDR, false discovery rate; OR, odds ratio; PSM, propensity score matching.

Supplementary Table 2. Results of the sensitivity analysis for cognition in liver enzymes within the PSM cohort

	Language		Visuospatial		Memory		Executive	
	β (SE)	p [a]	β (SE)	p [a]	β (SE)	p [a]	β (SE)	p [a]
AST, U/L	0.004 (0.012)	0.75	0.029 (0.019)	0.13	-0.001 (0.010)	0.90	0.0002 (0.008)	0.98
ALT, U/L	0.003 (0.010)	0.78	0.028 (0.016)	0.08	0.013 (0.008)	0.0868	0.007 (0.007)	0.30
AST-to-ALT ratio	0.003 (0.124)	0.98	-0.119 (0.195)	0.54	-0.191 (0.087)	0.03	-0.074 (0.085)	0.38
ALP, U/L	-0.003 (0.004)	0.43	0.0003 (0.006)	0.96	-0.002 (0.003)	0.59	0.001 (0.003)	0.72
Total bilirubin, mg/dL	0.387 (0.354)	0.28	0.247 (0.556)	0.66	-0.213 (0.265)	0.42	-0.165 (0.242)	0.50
Albumin, g/dL	0.206 (0.246)	0.40	0.349 (0.390)	0.37	0.261 (0.188)	0.16	0.086 (0.170)	0.61

All analyses were adjusted for years of education and prevalence of hypertension, diabetes mellitus, dyslipidemia, and statin use.

[a] Adjusted p value for FDR

ALP, alkaline phosphatase; ALT, alanine aminotransferase; *APOE*, apolipoprotein E; AST, aspartate aminotransferase; FDR, false discovery rate; SE, standard error.